Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 412 results for heart failure

  1. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

  2. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  3. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  4. Cardiac contractility modulation device implantation for heart failure (IPG655)

    We have moved interventional procedures guidance 655 to become HealthTech guidance 520. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. CytoSorb therapy for sepsis (MIB87)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .

  6. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

  7. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.

  8. VA ECMO for severe acute heart failure in adults (IPG807)

    We have moved interventional procedures guidance 807 to become HealthTech guidance 764. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  9. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  10. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  11. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

  12. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    We have moved Medical technologies guidance 33 to become HealthTech guidance 433. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Permanent His-bundle pacemaker implantation for treating heart failure (IPG694)

    We have moved interventional procedures guidance 694 to become HealthTech guidance 579. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

  15. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.